Purchase Order 75N91020P00738

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc., valued at $239,190.00, for procurement of an Illumina NextSeq 2000 sequencing system and trade-in of an Illumina NextSeq 500 sequencing system, with an award date of August 26, 2020. Place of performance is San Diego, California. The order was structured as a firm fixed-price purchase order with no set-aside designation and carries an ultimate completion date of October 28, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $60,292.06 on August 20, 2015, for service on Illumina HiSeq and two NextSeq sequencing instruments. Work is performed in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of February 19, 2016.</p>

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on August 17, 2018, for genetic sequencing and genomic analysis technologies.</p> <p>Place of performance is Bethesda, MD. The order has a firm fixed-price pricing structure and an ultimate completion date of September 15, 2018. Illumina manufactures advanced DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software supporting genomic research across federal agencies.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on July 26, 2017, with a ceiling value of $22,188.47 for genetic sequencing equipment and consumables, with ultimate completion by August 28, 2017.</p> <p>Place of performance is Bethesda, MD. The order is firm fixed price with no set-aside designation. Illumina specializes in DNA and RNA sequencing instruments, reagents, and bioinformatics software supporting genomic research across federal agencies.</p>

The National Cancer Institute awarded a purchase order to Illumina, Inc. for an Illumina MiSeq i100 Series System on June 1, 2026, with a ceiling value of $111,115.79 and an ultimate completion date of August 24, 2026. The system is firm fixed price with no set-aside designation. Place of performance is Bethesda, Maryland. The acquisition was conducted as a sole-source procurement under FAR 6.302-1 authority through the Interior Business Center, with Illumina identified as the sole capable...

The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents, to provide an Illumina NextSeq 2000 genetic analysis sequencer. The sequencer will be used to acquire whole genome, whole exome, and whole transcriptome data to support the National Cancer Institute's efforts to develop novel cancer...

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on October 23, 2017, with a ceiling value of $6,892.55. Place of performance is Bethesda, MD. The order is for genetic sequencing equipment, reagents, or consumables consistent with Illumina's portfolio of DNA and RNA sequencing instruments and bioinformatics software supporting genomic research. The ultimate completion date is November 19, 2017. The order is priced as firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on July 23, 2015, with a ceiling value of $24,772.41 for genomic sequencing equipment and reagents.</p> <p>Place of performance is Baltimore, Maryland. The order was firm fixed price with no set-aside. Ultimate completion date was April 12, 2020.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on September 7, 2017, with a ceiling value of $6,700.18.</p> <p>Place of performance is Bethesda, MD 20892. The order has a firm fixed-price structure and an ultimate completion date of October 8, 2017. The delivery order calls for genetic sequencing equipment, reagents, consumables, or bioinformatics software consistent with Illumina's portfolio of DNA and RNA sequencing instruments and analytical tools.</p>

<p>The National Cancer Institute issued a $13,402.80 delivery order to Illumina, Inc. on May 20, 2019, for NSQ 500/550 high-output sequencing kits (150 units) on a firm fixed-price basis.</p> <p>Place of performance is San Diego, CA 92122. The order was due for completion on June 19, 2019. No set-aside was applied.</p>